|
Clinical Trials
Cellectar is scheduled to file its IND application with the FDA in the coming weeks.
Cellectar will focus clinical development on the potential for 131I-CLR1404 to be an adjunctive and/or curative therapy for several solid tumors. Additional trials for diagnostic indications will follow.
Our initial Phase 1 trial will be open to all solid tumors, and we have specific interest in:
- Non-small cell lung cancer (NSCLC)
- Pancreatic cancer
- Primary or metastatic brain cancer
|
